CI vs ZBH: fair value comparison
The Cigna Group and Zimmer Biomet Holdings, Inc. · Updated 2026-10-19
Both currently screen as undervalued on TickrTrends' Forward Fair Value model. Within Healthcare, ZBH currently sits closer to the top of our ranking by discount to fair value. ZBH carries the stronger quality grade.
| CI | ZBH | |
|---|---|---|
| Verdict | Undervalued | Undervalued |
| Last price | $282.43 | $89.14 |
| 12-month range | $244.41–$309.18 | $79.58–$103.18 |
| Rank by discount to fair value | #28 of 108 Healthcare | #24 of 108 Healthcare |
| Quality grade | F | B |
| Leverage | Moderate | Moderate |
| Margin trend | Expanding | Contracting |
| Revenue growth | Strong | Modest |
| RSI zone | Overbought | Neutral |
| DCF cross-check | Undervalued | Fairly Valued |
| 52-week position | The upper-middle quarter | The lower-middle quarter |
Full single-stock breakdowns: CI fair value analysis · ZBH fair value analysis